Novavax Inc (NVAX)

[TRUISM]

Novavax Losses Widen On Expenses
Jeff Clabaugh--Feb 26, 2015, 5:15pm EST UPDATED: Feb 26, 2015, 5:22pm EST
Click For bizjournals.com Article


Gaithersburg-based Novavax Inc., which began early stage clinical trials for an Ebola vaccine, reports wider quarterly losses on an increase in R&D expenses.

Gaithersburg-based Novavax Inc. posted higher full year revenue, but rising research and development costs and a growing workforce increased expenses and widened fourth quarter losses.
Novavax reports a fourth quarter net loss of $31.5 million, or 13 cents per share, compared to a net loss of $14.1 million, or 7 cents per share in the same quarter a year ago.
Fourth quarter revenue was $6.7 million, down 23 percent.
For all of 2014, Novavax had $30.7 million in revenue, an increase of 47 percent.
Novavax is spending more to ramp up clinical research and trials on a number of new candidates, including new influenza vaccines.
The company recently began early stage clinical trials of an Ebola vaccine.

TRUTH